Summary & Overview
HCPCS J9040: Injection, Bleomycin Sulfate, 15 Units
HCPCS Level II code J9040 represents an injection of bleomycin sulfate in 15-unit increments, a parenteral antineoplastic agent used in oncology. Nationally, accurate coding of drug J-codes is essential for claims processing, clinical tracking, and cost management for cancer therapies. This code matters because it standardizes billing for a cytotoxic agent that may be used across multiple malignancies and care settings.
Key payers in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find an overview of how the code is used clinically and operationally, typical sites of service where the drug is administered, and the payers most commonly involved in coverage decisions. The publication summarizes available benchmarks, identifies common billing and documentation considerations, and flags areas where policy updates or payer edits commonly appear.
This briefing is intended for billing managers, revenue cycle teams, oncology clinicians, and policy analysts seeking concise guidance about the clinical and administrative context of HCPCS Level II code J9040. Data not available in the input will be noted where applicable.
Billing Code Overview
HCPCS Level II code J9040 describes an injection of bleomycin sulfate, measured per 15 units. This code represents a parenteral chemotherapy agent administered for oncologic indications.
Service type: Drug administration (injectable antineoplastic agent)
Typical site of service: Outpatient infusion center, hospital outpatient department, or clinic
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A typical patient is an adult referred to an oncology or dermatology clinic for administration of intralesional or systemic bleomycin sulfate for treatment of malignancy or refractory vascular lesions. The presenting scenario often involves a patient with a diagnosis such as squamous cell carcinoma, basal cell carcinoma, Kaposi sarcoma, or a recalcitrant hypertrophic keloid or vascular malformation. A clinician or infusion nurse reviews pertinent labs (renal function, pulmonary status), documents informed consent and allergy status, and confirms the indication and dosing. The service described by J9040 (Injection, bleomycin sulfate, 15 units) is prepared in the clinic or infusion suite, administered either intralesionally, intradermally, or intravenously depending on indication, and monitored for immediate adverse reactions. Post-administration, the patient is observed for a short period for local site reactions, respiratory symptoms, or other acute toxicity. Documentation includes drug name and dose in units, route, site of administration, lot number, expiration, consent, and any immediate adverse effects. Typical site of service is an outpatient oncology infusion center, dermatology clinic, outpatient hospital clinic, or ambulatory surgical center for localized injections.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
JW | Drug amount discarded/not administered |